The new edition of the 2016 World Health Organization (WHO) classification system for
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …

Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …

Title A guideline for the diagnosis and management of polycythaemia vera A British Society for
Haematology Guideline Authors Mc Page 1 1 Title 1 A guideline for the diagnosis and …

Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-
ABL1-negative myeloproliferative neoplasms and are characterized by relatively long …

Bone marrow fibrosis is a central pathological feature and World Health Organization major
diagnostic criterion of myelofibrosis. Although bone marrow fibrosis is seen in a variety of …

Recently reported mature survival data have confirmed the favorable prognosis in
polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger …

Abstract The 2001/2008 World Health Organization (WHO)-based diagnostic criteria for
polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) …

We examined the baseline features and clinical outcomes of 140 patients presenting with
JAK2V617F positivity and a bone marrow morphology conforming with WHO criteria of …